Virus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges)

Viruses. 2016 Apr 8;8(4):94. doi: 10.3390/v8040094.

Abstract

Marburg virus (MARV) was the first filovirus to be identified following an outbreak of viral hemorrhagic fever disease in Marburg, Germany in 1967. Due to several factors inherent to filoviruses, they are considered a potential bioweapon that could be disseminated via an aerosol route. Previous studies demonstrated that MARV virus-like particles (VLPs) containing the glycoprotein (GP), matrix protein VP40 and nucleoprotein (NP) generated using a baculovirus/insect cell expression system could protect macaques from subcutaneous (SQ) challenge with multiple species of marburgviruses. In the current study, the protective efficacy of the MARV VLPs in conjunction with two different adjuvants: QS-21, a saponin derivative, and poly I:C against homologous aerosol challenge was assessed in cynomolgus macaques. Antibody responses against the GP antigen were equivalent in all groups receiving MARV VLPs irrespective of the adjuvant; adjuvant only-vaccinated macaques did not demonstrate appreciable antibody responses. All macaques were subsequently challenged with lethal doses of MARV via aerosol or SQ as a positive control. All MARV VLP-vaccinated macaques survived either aerosol or SQ challenge while animals administered adjuvant only exhibited clinical signs and lesions consistent with MARV disease and were euthanized after meeting the predetermined criteria. Therefore, MARV VLPs induce IgG antibodies recognizing MARV GP and VP40 and protect cynomolgus macaques from an otherwise lethal aerosol exposure with MARV.

Keywords: Marburg virus; adjuvant; aerosol; macaque; vaccine; virus-like particle.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Antibodies, Viral / immunology
  • Antigens, Viral / immunology
  • Immunoglobulin G / immunology
  • Liver / immunology
  • Liver / metabolism
  • Liver / pathology
  • Macaca fascicularis
  • Marburg Virus Disease / immunology
  • Marburg Virus Disease / prevention & control*
  • Marburg Virus Disease / virology
  • Marburgvirus / immunology*
  • Spleen / immunology
  • Spleen / metabolism
  • Spleen / pathology
  • Time Factors
  • Treatment Outcome
  • Vaccination*
  • Vaccines, Virus-Like Particle / administration & dosage
  • Vaccines, Virus-Like Particle / immunology*
  • Viremia / virology

Substances

  • Antibodies, Viral
  • Antigens, Viral
  • Immunoglobulin G
  • Vaccines, Virus-Like Particle